Linagliptin inhibits lipopolysaccharide-induced inflammation in human U937 monocytes

BACKGROUND: Atherosclerosis and inflammation are more common in patients with diabetes than in patients without diabetes, and atherosclerosis progression contributes to inflammation. Therefore, anti-inflammatory therapy is important for the prognosis of patients with diabetes. Linagliptin is the onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamadera, Shiho, Nakamura, Yuya, Inagaki, Masahiro, Kenmotsu, Sachiyo, Nohara, Tetsuhito, Sato, Naoki, Oguchi, Tatsunori, Tsuji, Mayumi, Ohsawa, Isao, Gotoh, Hiromichi, Goto, Yoshikazu, Yura, Akihiko, Kiuchi, Yuji, Iwai, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100723/
https://www.ncbi.nlm.nih.gov/pubmed/30151063
http://dx.doi.org/10.1186/s41232-018-0071-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100723/
https://www.ncbi.nlm.nih.gov/pubmed/30151063
http://dx.doi.org/10.1186/s41232-018-0071-z

Ejemplares similares